From WATTAgNet:Zoetis on November 4 reported revenue of $1.2 billion for the third quarter of 2014, an increase of 10 percent from the third quarter of 2013. Revenue reflected an operational  increase of 10 percent, with foreign currency having no material impact on revenue growth this quarter.Net income for the third quarter of 2014 was $166 million, an increase of 27 percent, compared to the third quarter of 2013. “This quarter’s performance was driven largely by 13 percent operational revenue growth in our livestock products and continued discipline around our operating expenses,” said Zoetis Chief Executive Officer Juan Ramón Alaix.Zoetis organizes and manages its business across four regional operating segments: the United States (U.S.); Europe/Africa/Middle East (EuAfME); Canada/Latin America (CLAR); and Asia/Pacific (APAC). In each of those regional segments, the company experienced a revenue increase during the third quarter of 2014.Revenue in the U.S. was $532 million, an increase of 7 percent.  Revenue in EuAfME was $293 million, an increase of 12 percent operationally. Revenue in CLAR was $194 million, an increase of 17 percent, and revenue in APEC increased 7 percent operationally to $179 million.“All of our geographical segments benefited from the strong sales of livestock products in the quarter. We saw an increase in the use of our premium cattle products in key markets, as well as continued acceptance of new products in our swine and poultry portfolios," said Alaix. 

Advertisement

Zoetis Q3 Results Top Estimates, Backs 2014 EPS Outlook

(RTTNews) - Zoetis, Inc. (ZTS), the former animal health business of Pfizer, Inc. (PFE), reported Tuesday a profit for the third quarter that grew 27 percent from last year, reflecting improved revenues across operating segments and regions. Both adjusted earnings per share and quarterly revenues topped analysts' expectations.
Read more at www.quotenet.com

Zoetis Beats Wall Street Third Quarter Profit Forecasts

Zoetis Inc. has reported third-quarter profit of $166 million. On a per-share basis, the Florham Park, New Jersey-based company said it had profit of 33 cents. Earnings, adjusted for non-recurring costs, came to 41 cents per share. The results surpassed Wall Street expectations.
Read more at Pharmpro